You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTolcapone
Accession NumberDB00323  (APRD00445)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionTolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. [Wikipedia]
Structure
Thumb
Synonyms
(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone
3,4-Dihydroxy-4'-methyl-5-nitrobenzophenone
3,4-Dihydroxy-5-nitro-4'-methylbenzophenone
4'-Methyl-3,4-dihydroxy-5-nitrobenzophenone
Tolcapon
Tolcapona
Tolcapone
Tolcaponum
External Identifiers
  • Ro 40-7592
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TasmarFilm-coated tablet200 mgOral useMeda Ab1997-08-27Not applicableEu
Tasmartablet, film coated100 mg/1oralValeant Pharmaceuticals North America LLC2004-07-27Not applicableUs
TasmarFilm-coated tablet100 mgOral useMeda Ab1997-08-27Not applicableEu
TasmarFilm-coated tablet100 mgOral useMeda Ab1997-08-27Not applicableEu
TasmarFilm-coated tablet200 mgOral useMeda Ab1997-08-27Not applicableEu
TasmarFilm-coated tablet100 mgOral useMeda Ab1997-08-27Not applicableEu
TasmarFilm-coated tablet100 mgOral useMeda Ab1997-08-27Not applicableEu
TasmarFilm-coated tablet200 mgOral useMeda Ab1997-08-27Not applicableEu
Tasmartablet100 mgoralHoffmann La Roche Limited1997-10-201999-01-11Canada
TasmarFilm-coated tablet100 mgOral useMeda Ab1997-08-27Not applicableEu
TasmarFilm-coated tablet100 mgOral useMeda Ab1997-08-27Not applicableEu
Tasmartablet200 mgoralHoffmann La Roche Limited1997-10-201999-01-11Canada
Tolcaponetablet, film coated100 mg/1oralOceanside Pharmaceuticals2004-07-27Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tolcaponetablet, coated100 mg/1oralPar Pharmaceutical Inc.2015-01-06Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Sen De NingDexin Runsheng Pharmaceutical
Brand mixturesNot Available
SaltsNot Available
Categories
UNIICIF6334OLY
CAS number134308-13-7
WeightAverage: 273.2408
Monoisotopic: 273.063722467
Chemical FormulaC14H11NO5
InChI KeyInChIKey=MIQPIUSUKVNLNT-UHFFFAOYSA-N
InChI
InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3
IUPAC Name
5-(4-methylbenzoyl)-3-nitrobenzene-1,2-diol
SMILES
CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzophenones
Direct ParentBenzophenones
Alternative Parents
Substituents
  • Benzophenone
  • Diphenylmethane
  • Nitrophenol derivative
  • Nitrobenzene
  • Acetophenone
  • Aryl ketone
  • 1,2-diphenol
  • Benzoyl
  • Toluene
  • Phenol
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Ketone
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Organic zwitterion
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed as an adjunct to levodopa/carbidopa therapy for the symptomatic treatment of Parkinson's Disease. This drug is generally reserved for patients with parkinsonian syndrome receiving levodopa/carbidopa who are experiencing symptom fluctuations and are not responding adequately to or are not candidates for other adjunctive therapies.
PharmacodynamicsTolcapone is a potent, selective, and reversible inhibitor of catechol-O-methyltransferase (COMT). In humans, COMT is distributed throughout various organs. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. COMT is responsible for the elimination of biologically active catechols and some other hydroxylated metabolites. In the presence of a decarboxylase inhibitor, COMT becomes the major metabolizing enzyme for levodopa catalyzing it to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the brain and periphery. When tolcapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that these sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to greater effects on the signs and symptoms of Parkinson's disease in patients as well as increased levodopa adverse effects, sometimes requiring a decrease in the dose of levodopa.
Mechanism of actionThe precise mechanism of action of tolcapone is unknown, but it is believed to be related to its ability to inhibit COMT and alter the plasma pharmacokinetics of levodopa, resulting in an increase in plasma levodopa concentrations. The inhibition of COMT also causes a reduction in circulating 3-OMD as a result of decreased peripheral metabolism of levodopa. This may lead to an increase distribution of levodopa into the CNS through the reduction of its competitive substrate, 3-OMD, for transport mechanisms. Sustained levodopa concentrations presumably result in more consistent dopaminergic stimulation, resulting in greater reduction in the manifestations of parkinsonian syndrome.
Related Articles
AbsorptionRapidly absorbed (absolute bioavailability is about 65%)
Volume of distribution
  • 9 L
Protein binding> 99.9% (to serum albumin)
Metabolism

The main metabolic pathway of tolcapone is glucuronidation

Route of eliminationTolcapone is almost completely metabolized prior to excretion, with only a very small amount (0.5% of dose) found unchanged in urine. The glucuronide conjugate of tolcapone is mainly excreted in the urine but is also excreted in the bile.
Half life2-3.5 hours
Clearance
  • 7 L/h
ToxicityLD50 = 1600 mg/kg (Orally in rats)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9041
Blood Brain Barrier-0.9418
Caco-2 permeable-0.5422
P-glycoprotein substrateNon-substrate0.6612
P-glycoprotein inhibitor INon-inhibitor0.6371
P-glycoprotein inhibitor IINon-inhibitor0.9128
Renal organic cation transporterNon-inhibitor0.933
CYP450 2C9 substrateNon-substrate0.6554
CYP450 2D6 substrateNon-substrate0.894
CYP450 3A4 substrateSubstrate0.5245
CYP450 1A2 substrateNon-inhibitor0.9199
CYP450 2C9 inhibitorInhibitor0.8317
CYP450 2D6 inhibitorNon-inhibitor0.9135
CYP450 2C19 inhibitorNon-inhibitor0.8762
CYP450 3A4 inhibitorNon-inhibitor0.6585
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5984
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6079
BiodegradationNot ready biodegradable0.9433
Rat acute toxicity2.2574 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8346
hERG inhibition (predictor II)Non-inhibitor0.8311
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Valeant pharmaceuticals international
Packagers
Dosage forms
FormRouteStrength
Film-coated tabletOral use100 mg
Film-coated tabletOral use200 mg
Tabletoral100 mg
Tabletoral200 mg
Tablet, film coatedoral100 mg/1
Tablet, coatedoral100 mg/1
Prices
Unit descriptionCostUnit
Tasmar 100 mg tablet8.13USD tablet
Tasmar 200 mg tablet7.44USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5236952 No1995-01-292012-01-29Us
US5476875 No1992-12-192012-12-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0569 mg/mLALOGPS
logP2.63ALOGPS
logP3.28ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)5.17ChemAxon
pKa (Strongest Basic)-6.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area103.35 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity72.96 m3·mol-1ChemAxon
Polarizability26.44 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Guay DR: Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Pharmacotherapy. 1999 Jan;19(1):6-20. [PubMed:9917075 ]
  2. Keating GM, Lyseng-Williamson KA: Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs. 2005;19(2):165-84. [PubMed:15697329 ]
  3. Truong DD: Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging. 2009;4:109-13. Epub 2009 May 14. [PubMed:19503773 ]
  4. Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506. [PubMed:12538800 ]
  5. Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233-50. [PubMed:10882160 ]
External Links
ATC CodesN04BX01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (71.3 KB)
MSDSDownload (17.3 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tolcapone.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Tolcapone is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tolcapone.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tolcapone.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Tolcapone.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tolcapone.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tolcapone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tolcapone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tolcapone.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tolcapone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tolcapone.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tolcapone.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tolcapone.
AmoxapineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Tolcapone.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tolcapone.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Tolcapone.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tolcapone.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Tolcapone.
AzelastineTolcapone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tolcapone.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Tolcapone.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Tolcapone.
BenmoxinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Benmoxin.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tolcapone.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tolcapone.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.
BrimonidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tolcapone.
BrompheniramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Tolcapone.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tolcapone.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tolcapone.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tolcapone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tolcapone.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Tolcapone.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Tolcapone.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Tolcapone.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Tolcapone.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tolcapone.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tolcapone.
CarbinoxamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Tolcapone.
CarisoprodolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Carisoprodol.
CaroxazoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Caroxazone.
CetirizineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tolcapone.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tolcapone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Tolcapone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tolcapone.
ChlorphenamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tolcapone.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tolcapone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tolcapone.
CitalopramThe risk or severity of adverse effects can be increased when Tolcapone is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Tolcapone.
ClidiniumThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Tolcapone.
ClomipramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tolcapone.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tolcapone.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tolcapone.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tolcapone.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Tolcapone.
CyclizineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tolcapone.
CyproheptadineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tolcapone.
DapoxetineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Tolcapone.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tolcapone.
DesipramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Tolcapone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tolcapone.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tolcapone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tolcapone.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Tolcapone.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tolcapone.
DiethylstilbestrolThe metabolism of Diethylstilbestrol can be decreased when combined with Tolcapone.
DifenoxinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tolcapone.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tolcapone.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tolcapone.
DimenhydrinateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tolcapone.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tolcapone.
DobutamineThe metabolism of Dobutamine can be decreased when combined with Tolcapone.
DopamineThe metabolism of Dopamine can be decreased when combined with Tolcapone.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Tolcapone.
DoxepinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.
DoxylamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Tolcapone.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Tolcapone.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Tolcapone.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tolcapone.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Tolcapone.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Tolcapone.
EfavirenzThe risk or severity of adverse effects can be increased when Tolcapone is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tolcapone.
EntacaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Tolcapone is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tolcapone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tolcapone.
EthanolTolcapone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Tolcapone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tolcapone.
EthosuximideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tolcapone.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tolcapone.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tolcapone.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Tolcapone.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Tolcapone.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Tolcapone.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tolcapone.
EtoperidoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tolcapone.
EzogabineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tolcapone.
FenfluramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tolcapone.
FexofenadineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tolcapone.
FlunarizineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tolcapone.
FluoxetineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tolcapone.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tolcapone.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tolcapone.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tolcapone.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tolcapone.
FurazolidoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Furazolidone.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tolcapone.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Tolcapone is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tolcapone.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Tolcapone.
GuanfacineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Tolcapone.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tolcapone.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tolcapone.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Tolcapone.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tolcapone.
HydracarbazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Hydracarbazine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tolcapone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tolcapone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.
HydroxyzineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Indalpine.
IproclozideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iproclozide.
IproniazidThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iproniazid.
IsocarboxazidThe risk or severity of adverse effects can be increased when Tolcapone is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tolcapone.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tolcapone.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tolcapone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tolcapone.
LamotrigineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tolcapone.
LevocabastineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tolcapone.
LevomilnacipranThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tolcapone.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tolcapone.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Tolcapone.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Tolcapone.
LoratadineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tolcapone.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tolcapone.
Lu AA21004The risk or severity of adverse effects can be increased when Tolcapone is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tolcapone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Maprotiline.
MebanazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Mebanazine.
MeclizineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Tolcapone.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Tolcapone.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Tolcapone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tolcapone.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tolcapone.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tolcapone.
MetaxaloneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Tolcapone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tolcapone.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tolcapone.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tolcapone.
MethocarbamolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tolcapone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Tolcapone.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tolcapone.
MethsuximideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methsuximide.
MethyldopaThe metabolism of Methyldopa can be decreased when combined with Tolcapone.
Methylene blueThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methylene blue.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tolcapone.
MetyrosineTolcapone may increase the sedative activities of Metyrosine.
MicafunginThe metabolism of Micafungin can be decreased when combined with Tolcapone.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tolcapone.
MilnacipranThe risk or severity of adverse effects can be increased when Tolcapone is combined with Milnacipran.
MinaprineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Minaprine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.
MirtazapineTolcapone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tolcapone.
MoclobemideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Moclobemide.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Tolcapone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tolcapone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.
NabiloneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tolcapone.
NialamideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nialamide.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tolcapone.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tolcapone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Tolcapone.
NortriptylineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nortriptyline.
OctamoxinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Octamoxin.
OlanzapineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tolcapone.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Tolcapone.
OrphenadrineTolcapone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tolcapone.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Tolcapone.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tolcapone.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tolcapone.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tolcapone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tolcapone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tolcapone.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tolcapone.
ParaldehydeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Tolcapone.
PargylineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pargyline.
ParoxetineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tolcapone.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tolcapone.
PerampanelThe risk or severity of adverse effects can be increased when Tolcapone is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Tolcapone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tolcapone.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tolcapone.
PhenelzineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Phenelzine.
PheniprazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pheniprazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tolcapone.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Tolcapone.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Phenoxypropazine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Tolcapone.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Tolcapone.
PipamperoneThe therapeutic efficacy of Pipamperone can be decreased when used in combination with Tolcapone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tolcapone.
PipotiazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pipotiazine.
PirlindoleThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pirlindole.
PivhydrazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pivhydrazine.
PizotifenThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pomalidomide.
PramipexoleTolcapone may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tolcapone.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Tolcapone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tolcapone.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tolcapone.
PrimidoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tolcapone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tolcapone.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Tolcapone.
PromethazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tolcapone.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tolcapone.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Tolcapone.
ProtriptylineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Tolcapone.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tolcapone.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tolcapone.
RamelteonThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ramelteon.
RasagilineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tolcapone.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tolcapone.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tolcapone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Tolcapone.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Tolcapone.
RopiniroleTolcapone may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tolcapone.
RotigotineTolcapone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tolcapone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tolcapone.
SafrazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Safrazine.
ScopolamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tolcapone.
SelegilineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Tolcapone.
SertralineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tolcapone.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Tolcapone.
StiripentolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tolcapone.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tolcapone.
SuvorexantThe risk or severity of adverse effects can be increased when Tolcapone is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tolcapone.
TetrabenazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tolcapone.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tolcapone.
ThalidomideTolcapone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tolcapone.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tolcapone.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tolcapone.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tolcapone.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tolcapone.
TiagabineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Tolcapone.
TizanidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tizanidine.
ToloxatoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Toloxatone.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tolcapone.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tolcapone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tolcapone.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tolcapone.
TrazodoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tolcapone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tolcapone.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tolcapone.
TrimipramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tolcapone.
VigabatrinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Tolcapone.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tolcapone.
ZiconotideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tolcapone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Tolcapone.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tolcapone.
ZonisamideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tolcapone.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Tolcapone.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tolcapone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
O-methyltransferase activity
Specific Function:
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
Gene Name:
COMT
Uniprot ID:
P21964
Molecular Weight:
30036.77 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Ries V, Selzer R, Eichhorn T, Oertel WH, Eggert K: Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. Clin Neuropharmacol. 2010 May;33(3):142-50. doi: 10.1097/WNF.0b013e3181d99d6f. [PubMed:20502133 ]
  3. Guay DR: Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Pharmacotherapy. 1999 Jan;19(1):6-20. [PubMed:9917075 ]
  4. Keating GM, Lyseng-Williamson KA: Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs. 2005;19(2):165-84. [PubMed:15697329 ]
  5. Truong DD: Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging. 2009;4:109-13. Epub 2009 May 14. [PubMed:19503773 ]
  6. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, Alce G, Iudicello JE, Akbar N, Egan MF, Goldberg TE, Weinberger DR: Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology. 2007 May;32(5):1011-20. Epub 2006 Oct 25. [PubMed:17063156 ]
  7. Stocchi F, De Pandis MF: Utility of tolcapone in fluctuating Parkinson's disease. Clin Interv Aging. 2006;1(4):317-25. [PubMed:18046910 ]
  8. Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506. [PubMed:12538800 ]
  9. Tai CH, Wu RM: Catechol-O-methyltransferase and Parkinson's disease. Acta Med Okayama. 2002 Feb;56(1):1-6. [PubMed:11873938 ]
  10. Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233-50. [PubMed:10882160 ]
  11. Ruottinen HM, Rinne UK: COMT inhibition in the treatment of Parkinson's disease. J Neurol. 1998 Nov;245(11 Suppl 3):P25-34. [PubMed:9808337 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23